These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25430078)

  • 21. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
    Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
    Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
    Fukihara J; Kondoh Y
    Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
    Rodríguez-Portal JA
    Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dacomitinib: First Global Approval.
    Shirley M
    Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Mazzei ME; Richeldi L; Collard HR
    Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE.
    Kolonics-Farkas AM; Šterclová M; Mogulkoc N; Kus J; Hájková M; Müller V; Jovanovic D; Tekavec-Trkanjec J; Littnerová S; Hejduk K; Vašáková M
    Drug Saf; 2020 Oct; 43(10):971-980. PubMed ID: 32734423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.
    Dallinger C; Trommeshauser D; Marzin K; Liesener A; Kaiser R; Stopfer P
    J Clin Pharmacol; 2016 Nov; 56(11):1387-1394. PubMed ID: 27093880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nintedanib-induced glomerular microangiopathy: a case report.
    Hasegawa M; Uehara A; Suzuki T; Sekine R; Yazawa M; Ichikawa D; Koike J; Shibagaki Y
    CEN Case Rep; 2020 Nov; 9(4):295-300. PubMed ID: 32279192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is nintedanib effective for idiopathic pulmonary fibrosis?
    Jeldres A; Labarca G
    Medwave; 2017 Apr; 17(Suppl2):e6918. PubMed ID: 28430774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expert Knowledge and Supporting Advice for the Clinical Use of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis].
    Behr J; Günther A; Kreuter M; Koschel D; Prasse A; Pfeifer M; Costabel U
    Pneumologie; 2017 Sep; 71(9):567-579. PubMed ID: 28772332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
    Reck M; Heigener D; Reinmuth N
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):579-90. PubMed ID: 25119062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma.
    Grohé C; Gleiber W; Haas S; Losem C; Mueller-Huesmann H; Schulze M; Franke C; Basara N; Atz J; Kaiser R
    Future Oncol; 2019 Aug; 15(23):2699-2706. PubMed ID: 31282758
    [No Abstract]   [Full Text] [Related]  

  • 35. Nintedanib - efficacy, safety and practical aspects of treatment for patients with idiopathic pulmonary fibrosis.
    Martusewicz-Boros M; Górska K
    Adv Respir Med; 2020; 88(6):599-607. PubMed ID: 33393653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fruquintinib: First Global Approval.
    Shirley M
    Drugs; 2018 Nov; 78(16):1757-1761. PubMed ID: 30357594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.
    Barczi E; Starobinski L; Kolonics-Farkas A; Eszes N; Bohacs A; Vasakova M; Hejduk K; Müller V
    Adv Ther; 2019 May; 36(5):1221-1232. PubMed ID: 30877478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Nintedanib in the treatment of fibrosing interstital lung diseases].
    Lewandowska K
    Pol Merkur Lekarski; 2018 Mar; 44(261):139-141. PubMed ID: 29601564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
    Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
    Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
    Woodcock HV; Molyneaux PL; Maher TM
    Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.